Elanco finalizes acquisition of Janssen Animal Health
Brussels, Belgium -- Elanco, the animal health division of Eli Lilly and Co., finalized its acquisition of the animal health business of Janssen Pharmaceutica, a Johnson & Johnson company.
Brussels, Belgium
— Elanco, the animal health division of Eli Lilly and Co., finalized its acquisition of the animal health business of Janssen Pharmaceutica, a Johnson & Johnson company.
The acquisition was approved July 7 by the European Commission and will further Elanco’s growth in Europe, according to the company. Elanco says the acquisition will diversify its food-animal portfolio and compliment its companion-animal business.
Terms of the deal have not been disclosed.
FDA approves oral drug for broad canine protection against parasites
October 7th 2024Elanco's lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets (Credelio Quattro) provide a single monthly dose for protection against fleas, ticks, heartworms, roundworms, hookworms, and 3 species of tapeworm.
Read More
dvm360 announces winners of the Veterinary Heroes program
Published: September 6th 2024 | Updated: November 5th 2024This year’s event is supported by corporate sponsor Schwarzman Animal Medical Center and category sponsors Blue Buffalo Natural, MedVet, Banfield Pet Hospital, Thrive Pet Healthcare and PRN Pharmacal.
Read More
